Altamira Therapeutics Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CHF 0.105469 million compared to CHF 0.290798 million a year ago. Net loss was CHF 5.42 million compared to CHF 8.24 million a year ago.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.45 USD | -3.33% | -11.59% | -58.33% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-58.33% | 3.25M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- CYTO Stock
- News Altamira Therapeutics Ltd.
- Altamira Therapeutics Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023